Hetero Ring Is Six-membered Consisting Of Three Nitrogens And Three Carbon Atoms Patents (Class 514/241)
-
Patent number: 8476434Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.Type: GrantFiled: November 22, 2010Date of Patent: July 2, 2013Assignee: Amgen Inc.Inventors: Stephanie D. Geuns-Meyer, Brian L. Hodous, Stuart C. Chaffee, Paul Tempest, Ning Xi, Phillip R. Olivieri, Joseph L. Kim, Steven Bellon, Xiaotian Zhu, Yuan Cheng, Brian K. Albrecht, Vinod F. Patel, Victor J. Cee, Karina Romero, Hanh Nho Nguyen, Holly L. Deak, Rebecca E. Johnson
-
Publication number: 20130143886Abstract: The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.Type: ApplicationFiled: January 30, 2013Publication date: June 6, 2013Applicant: Takeda Pharmaceuticals U.S.A., Inc.Inventor: Takeda Pharmaceuticals U.S.A., Inc.
-
Patent number: 8455252Abstract: Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant cancer cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant. Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins.Type: GrantFiled: October 24, 2009Date of Patent: June 4, 2013Assignee: Indiana University Research and Technology Corp.Inventors: Jian-Ting Zhang, Jing Qi, Hui Peng, Zizheng Dong
-
Patent number: 8449898Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, wherein R1, R2, A, G, W, Z1, X, J, and n are as defined in the disclosure, and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of the aforesaid composition. Also disclosed is a composition comprising component (a) of aforesaid composition and at least one insecticide. Also disclosed are compounds of Formula 1A, 1B and 1C, wherein R1, R2, A, G, W, Z1, X, J, n, Z3, M and J1 are as defined in the disclosure.Type: GrantFiled: October 23, 2008Date of Patent: May 28, 2013Assignee: E I du Pont de Nemours and CompanyInventors: Vann Gregory, Robert James Pasteris, Mary Ann Hanagan
-
Patent number: 8445490Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: April 13, 2011Date of Patent: May 21, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
-
Publication number: 20130101680Abstract: The present invention relates to a method of treating pancreatic cancer in a subject in need thereof by administering an effective amount of a composition containing (A) tegafur and (B) gimeracil in conjunction with radiotherapy.Type: ApplicationFiled: December 17, 2012Publication date: April 25, 2013Inventor: Masakazu FUKUSHIMA
-
Publication number: 20130101683Abstract: The invention is directed to compositions and methods of their use as effective biocidal agents for water streams. The composition comprises a halogen source, halogen stabilizers containing a sulfur bearing species and ammonium salts/urea, and an alkali. The sulfur bearing species includes sulfamic acid or its salt equivalent. By having optimized mixing ratio of halogen to stabilizer and that of ammonium salts to sulfamic acid or sulfamate, a synergistic effect occurs which both increases the efficacy of the composition as a biocide and it avoids adverse impacts on other chemicals that are present in the water stream. Best of all the composition is easy to form and easy to introduce into a water stream of concern. Its introduction can be as simple as mixing two containers of reagent prior to introduction to the water process stream.Type: ApplicationFiled: November 4, 2011Publication date: April 25, 2013Applicant: NALCO COMPANYInventors: Wen Li TU, Laura E. RICE, Andrew J. COOPER, Elisa M. LUTH, Yu-mei LU, Jian Kun SHEN
-
Patent number: 8410097Abstract: Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for the CB1 or CB2 cannabinoid receptor. Also disclosed are pharmaceutical preparations employing the disclosed analogs and methods of administering therapeutically effective amounts of the disclosed analogs to provide a physiological effect.Type: GrantFiled: December 22, 2011Date of Patent: April 2, 2013Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Rajesh Thotapally, Venkata Kiran Rao Vemuri, Teresa Olszewska
-
Patent number: 8410096Abstract: Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer.Type: GrantFiled: November 12, 2010Date of Patent: April 2, 2013Assignees: Shizuoka Prefecture, Taiho Pharmaceutical Co., Ltd.Inventor: Sung Hwa Park
-
Publication number: 20130078309Abstract: An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative.Type: ApplicationFiled: November 19, 2012Publication date: March 28, 2013Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: TAIHO PHARMACEUTICAL CO., LTD.
-
Patent number: 8389734Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: October 10, 2008Date of Patent: March 5, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Weichuan Caroline Chen, Paul Krenitsky, Andreas Termin, Dean Wilson
-
Patent number: 8362241Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.Type: GrantFiled: April 27, 2010Date of Patent: January 29, 2013Assignee: Amgen Inc.Inventors: Noel D'Angelo, Fang-Tsao Hong, Mark H. Norman, Adrian L. Smith, Seifu Tadesse
-
Patent number: 8357129Abstract: Skin rejuvenation system and method in which a pure plant collagen carrier is saturated with a solution of collagen, allantoin, amino acid, propanediol, glycerin, algae, plant DNA living cells, epidermal growth factor, Vitamin E, hyaluronic acid, rose essential, water, and peptide, and the saturated carrier is applied to the skin to be rejuvenated.Type: GrantFiled: November 10, 2010Date of Patent: January 22, 2013Assignee: Physicans Products, Inc.Inventors: Janet R. Graham, Douglas A. Ginter
-
Patent number: 8349834Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.Type: GrantFiled: December 7, 2006Date of Patent: January 8, 2013Assignee: Clavis Pharma ASInventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
-
Publication number: 20120328541Abstract: Compounds of the formulae and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula wherein G1 is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9-phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9-phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.Type: ApplicationFiled: September 5, 2012Publication date: December 27, 2012Inventors: Werner Baschong, Oliver Reich, Sébastien Mongiat
-
Patent number: 8338443Abstract: The use of a compound of formula I wherein Y is a single bond, C?O, C?S or S(O)m, where m is 0, 1 or 2; the ring is a 6-membered aromatic or is a 5 or 6 membered heteroaromatic ring; Z and Z? are joined by a single or a double bond and are ?C— or —N— provided that both are not N; Ra, R1, R2, R3, R3a, R4 and R8 are specified organic groups; n is 2, 3 or 4 and p is 0-4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.Type: GrantFiled: December 6, 2006Date of Patent: December 25, 2012Assignee: Syngenta Crop Protection LLCInventors: Jérôme Cassayre, Peter Maienfisch, Fredrik Cederbaum, Louis-Pierre Molleyres
-
Patent number: 8334316Abstract: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.Type: GrantFiled: February 9, 2009Date of Patent: December 18, 2012Assignee: ACEA Biosciences, Inc.Inventors: Xiao Xu, Haoyun An, Xiaobo Wang
-
Publication number: 20120316171Abstract: Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.Type: ApplicationFiled: November 4, 2010Publication date: December 13, 2012Inventor: Tamas Oravecz
-
Patent number: 8324380Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.Type: GrantFiled: October 23, 2008Date of Patent: December 4, 2012Assignee: Janssen Pharmaceutica NVInventors: Steven J. Coats, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara A. Miskowski, Janet L. Ralbovsky, Mark J. Schulz
-
Patent number: 8324379Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.Type: GrantFiled: May 16, 2011Date of Patent: December 4, 2012Assignee: Koronis Pharmaceuticals, Inc.Inventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev, Dina Sologub, Kevin Harris
-
Patent number: 8318702Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.Type: GrantFiled: July 4, 2008Date of Patent: November 27, 2012Assignee: Astellas Pharma Inc.Inventors: Yutaka Kondoh, Kazuhiko Iikubo, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani, Itsuro Shimada, Takahiro Matsuya, Kazuo Kurosawa, Akio Kamikawa, Hiroyuki Mano
-
Publication number: 20120282307Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8299253Abstract: Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylocholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and or gastrointestinal tract disorders.Type: GrantFiled: December 22, 2006Date of Patent: October 30, 2012Assignee: University of Kentucky Research FoundationInventors: Peter Crooks, Linda Dwoskin, Roger Papke, Guangrong Zheng, Sangeetha P Sumithran
-
Publication number: 20120237508Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.Type: ApplicationFiled: March 20, 2012Publication date: September 20, 2012Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
-
Publication number: 20120238578Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: May 23, 2012Publication date: September 20, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Zimmerman
-
Publication number: 20120207769Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).Type: ApplicationFiled: April 26, 2012Publication date: August 16, 2012Applicant: NOVARTIS AGInventors: Mark G. PALERMO, Sushil Kumar SHARMA, Christopher STRAUB, Run-Ming WANG, Leigh ZAWEL, Yanlin ZHANG, Zhuoliang CHEN, Yaping WANG, Fan YANG, Wojciech WRONA, Gang LIU, Mark G. CHAREST, Feng HE
-
Patent number: 8242113Abstract: Disclosed is a novel oxazolidinone derivative, particularly a novel oxazolidinone compound with a cyclic amidoxime or cyclic amidrazone group. Also disclosed is a pharmaceutical antibiotic composition including a novel oxazolidinone derivative, in vivo hydrolysable ester thereof, in vivo hydrolysable phosphate ester thereof, an isomer thereof or a pharmaceutically acceptable salt thereof as an effective ingredient. Because the novel oxazolidinone derivative, in vivo hydrolysable ester thereof, in vivo hydrolysable phosphate ester thereof, an isomer thereof or a pharmaceutically acceptable salt thereof exhibits a wide antibacterial spectrum against resistant bacteria, a low toxicity, and a strong antibacterial activity against Gram-positive and Gram-negative bacteria, it can be usefully used as an antibiotic.Type: GrantFiled: September 22, 2009Date of Patent: August 14, 2012Assignee: Legochem Biosciences, Inc.Inventors: Young Lag Cho, Sang Eun Chae, Sung Yoon Baek, Yeon Ok Kim, Seong Jin Kim, Hyang Sook Lee, Ju Hyun Park, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Patent number: 8236796Abstract: The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3 -a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle oType: GrantFiled: April 2, 2009Date of Patent: August 7, 2012Assignees: Albany Molecular Research, Inc., Bristol-Myers Squibb CompanyInventors: Bruce F. Molino, Shuang Liu, Peter R. Guzzo, James P. Beck
-
Patent number: 8231888Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CR3 and N; provided that at most 3 of A1, A2, A3, A4, A5 and A6 is N; B1, B2 and B3 are independently selected from the group consisting of CR2 and N; each R3 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, —CN or —NO2; and R1, R2, R4, R5, W and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.Type: GrantFiled: June 9, 2011Date of Patent: July 31, 2012Assignee: E.I. du Pont de Nemours and CompanyInventors: George Philip Lahm, Wesley Lawrence Shoop, Ming Xu
-
Patent number: 8227465Abstract: The present patent application relates to novel combinations of a triazine derivative and of an insulin secretion stimulator.Type: GrantFiled: December 18, 2006Date of Patent: July 24, 2012Assignee: Poxel SASInventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
-
Patent number: 8227599Abstract: A process for the separation of biological materials, such as dye-ligand affinity chromatography, wherein an adsorbent is used, which comprises a reaction product of certain reactive anthroquinone compounds and a substrate having a group capable of reaction with a reactive group in said reactive anthroquinone compounds to form a covalent bond.Type: GrantFiled: March 29, 2006Date of Patent: July 24, 2012Assignee: BASF SEInventors: Vadiraj Subbanna Ekkundi, Narayan S. Punekar, Kamalesh Pai Fondekar, Georg Roentgen, Shilpa S. Korde, Ajit B. Shinde, Masana Moorthy
-
Publication number: 20120184436Abstract: A synergistic antimicrobial composition. The composition contains at least two components. The first component is ortho-phenylphenol or its alkali metal or ammonium salts. The second component is 4,4-dimethyloxazolidine (DMOZ).Type: ApplicationFiled: September 15, 2010Publication date: July 19, 2012Inventor: Bei Yin
-
Publication number: 20120177745Abstract: The application describes synergistic microbicidal compositions comprising: 2,2-dibromomalonamide and an oxidizing biocide selected from the group consisting of: monochloramine, bromochlorodimethylhydantoin, hypobromite ion or hypobromous acid, hydrogen peroxide, dichloroisocyanurate, trichloroisocyanurate and chlorine dioxide and a method for controlling microorganism growth in an aqueous or water-containing system.Type: ApplicationFiled: September 27, 2010Publication date: July 12, 2012Inventors: Freddie L. Singleton, Bei Yin, Janardhanan S. Rajan
-
Publication number: 20120178758Abstract: The invention provides Styryl-Triazine derivatives, and further provides methods of using these compounds to modulate protein kinases and to treat protein kinase mediated diseases.Type: ApplicationFiled: June 8, 2010Publication date: July 12, 2012Applicant: CALIFORNIA CAPITAL EQUITY, LLCInventors: Chunlin Tao, Qinwei Wang, Neil Desai
-
Patent number: 8217039Abstract: Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific weight ratios of the forms.Type: GrantFiled: March 29, 2007Date of Patent: July 10, 2012Assignees: Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc.Inventors: Vijayavitthal Thippannachar Mathad, Pravinchandra Jayantilal Vankawala, Raviram Chandrasekhar Elati, Prabhakar Macharla, Srinivas Gangula, Naveen Kumar Kolla, Ravi Kumar Komareddy, Surya Narayana Devarkonda, Subbareddy Peddireddy
-
Patent number: 8217063Abstract: The present application relates to novel lactam-substituted dicarboxylic acid derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: GrantFiled: March 15, 2008Date of Patent: July 10, 2012Assignee: Bayer Intellectual Property GmbHInventors: Michael Hahn, Eva-Maria Becker, Andreas Knorr, Dirk Schneider, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Dieter Lang
-
Publication number: 20120172361Abstract: Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 7, 2010Publication date: July 5, 2012Applicant: CALIFORNIA CAPITAL EQUITY, LLCInventors: Chunlin Tao, Qinwei Wang, Tulay Polat, Laxman Nallan, David Ho, Neil Desai
-
Publication number: 20120141491Abstract: The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers, microbial/viral infections, and neurodegenerative diseases. Thus, the subject application also provides methods of treating various types of cancers, microbial/viral infections, and neurodegenerative diseases.Type: ApplicationFiled: August 9, 2010Publication date: June 7, 2012Applicant: University of Florida Research Foundation Inc.Inventors: William A. Dunn, Debra Everton Akin, Brian Keith Law
-
Patent number: 8188127Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.Type: GrantFiled: July 8, 2008Date of Patent: May 29, 2012Assignee: Rohm and Haas CompanyInventors: Richard Levy, Beverly Jean El A'mma, Beat Heer, Kiran Pareek
-
Patent number: 8188081Abstract: The present invention relates to prokineticin 1 receptor antagonists and methods of using the same to modulate intestine epithelial functions and to treat inflammation in the intestine in a mammal.Type: GrantFiled: June 9, 2010Date of Patent: May 29, 2012Assignee: Janssen Pharmaceutica, NVInventors: John R. Mabus, Jeffrey M. Palmer, Stephen M. Prouty, Pamela J. Hornby, Paul R. Wade
-
Publication number: 20120129862Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.Type: ApplicationFiled: May 23, 2011Publication date: May 24, 2012Inventors: Steven J. Coats, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara A. Miskowski, Janet L. Ralbovsky, Mark J. Schulz
-
Publication number: 20120129861Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: September 27, 2010Publication date: May 24, 2012Inventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20120121728Abstract: The invention provides a process of removing or preventing biofouling, particularly on surfaces of industrial and agricultural equipment in contact with aqueous liquids. The process employs an antifouling composition of stabilized active halogen having a low pH.Type: ApplicationFiled: June 7, 2010Publication date: May 17, 2012Applicant: BROMINE COMPOUNDS LTD.Inventors: Shlomo Antebi, Chen Zolkov, David Feldman
-
Patent number: 8178525Abstract: Disclosed are novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions containing the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.Type: GrantFiled: June 5, 2009Date of Patent: May 15, 2012Assignee: Legochem Bioscience Ltd.Inventors: Ho Young Song, Young Lag Cho, Dae Yon Lee, Hee Sock Park, Sung Yoon Baek, Sang Eun Chae, Sang Hui Jo, Yeon Ok Kim, Hyang Sook Lee, Ju Hyun Park, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Publication number: 20120108593Abstract: An extreme temperature decontamination composition such as a solution for destroying microorganisms, chemical warfare and bioterrorism agents is utilized that generally does not freeze at low temperatures down to about minus 25° F. and also has no significant evaporation or decomposition at temperatures up to about 120° F. The solution is effective against nerve agents and vesicants such as VX and HD, and various biological agents. The composition comprises a metallic salt of dichloroisocyanuric acid or dibromoisocyanuric acid, an aqueous solvent system comprising polar compounds such as water and an alkyl glycol, and a quasi hydrophilic compound. The composition can be formulated as a one part system wherein all components are blended together.Type: ApplicationFiled: August 19, 2010Publication date: May 3, 2012Applicant: AMERICAN STERILIZER COMPANYInventors: Herbert J. Kaiser, Daniel A. Klein, Anchalee Thanavaro, Miranda Chevon Shaver
-
Publication number: 20120101102Abstract: The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase.Type: ApplicationFiled: April 22, 2010Publication date: April 26, 2012Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hideyuki Akaza, Seiji Naito, Toshinori Oka
-
Publication number: 20120077806Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Publication number: 20120059009Abstract: To provide a novel combination therapy which exhibits remarkable anti-tumor effect. The invention provides an anti-tumor agent comprising a combination drug containing tegafur, gimeracil and oteracil potassium, oxaliplatin, and TSU-68 or a salt thereof, in combination.Type: ApplicationFiled: May 11, 2010Publication date: March 8, 2012Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Masakazu Fukushima
-
Patent number: 8114400Abstract: The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: GrantFiled: November 14, 2007Date of Patent: February 14, 2012Assignee: Bayer Pharma AktiengesellschaftInventors: Hartmut Schirok, Joachim Mittendorf, Johannes-Peter Stasch, Frank Wunder
-
Patent number: RE43748Abstract: Nitrogen-containing heterocyclic carboxamide derivatives represented by the following general formula: wherein ring A is a substituted or unsubstituted pyrazine, pyrimidine, pyridazine or triazine ring; R1 is O or OH; R2 is a hydrogen atom, an acyl group or a substituted or unsubstituted carbamoylalkyl or carboxyalkyl group; and the broken line represents a single bond or a double bond; or salts thereof are useful for preventing and treating virus infections and especially influenza virus infections.Type: GrantFiled: August 26, 2010Date of Patent: October 16, 2012Assignee: Toyama Chemical Co., Ltd.Inventors: Yousuke Furuta, Hiroyuki Egawa, Nobuhiko Nomura